REVERSE LC is a study to see if an FDA-approved drug called Baricitinib (ber-uh-sit-uh-nib), which is already used to treat COVID, can help improve thinking and memory problems and reduce fatigue for people who have Long COVID.
Who Can Participate?
Adults 18 and older who have had thinking and...
Open Access: Full article: Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases (tandfonline.com)
Abstract
It is well known that fatigue is a highly disabling symptom commonly observed in inflammatory rheumatic diseases (IRDs)...
REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)
The largest study on Long-Covid initiated by Wes Ely is starting in the upcoming months. In this large (n=550) Randomized, placebo-controlled, double-blind, parallel-design superiority design Phase 3 trial for Long-Covid 4 mg of...
The JAK/STAT signaling pathway: from bench to clinic
Hu, Xiaoyi; li, Jing; Fu, Maorong; Zhao, Xia; Wang, Wei
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular...
Abstract
The long-term health effects of SARS-CoV-2, termed Post-Acute Sequelae of COVID-19 (PASC), are quickly evolving into a major public health concern, but the underlying cellular and molecular etiology remain poorly defined. There is growing evidence that PASC is linked to abnormal immune...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.